Eric Easom - Jan 2, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Stock symbol
ANTX
Transactions as of
Jan 2, 2024
Transactions value $
-$55,802
Form type
4
Date filed
1/4/2024, 06:05 PM
Previous filing
May 15, 2023
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale -$55.8K -2.78K -56.59% $20.09 2.13K Jan 2, 2024 Direct F1
holding ANTX Common Stock 1.02M Jan 2, 2024 See Footnote F2
holding ANTX Common Stock 97.1K Jan 2, 2024 See Footnote F3
holding ANTX Common Stock 97.1K Jan 2, 2024 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2023.
F2 Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F3 Consists of shares of Common Stock held by the C Easom Irrevocable Trust dated October 8, 2021.
F4 Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.